Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neovascular Age-related Macular Degeneration: full-pipeline trial registry
7 of 34 indexed Neovascular Age-related Macular Degeneration trials are currently recruiting.
Corpus placement: #449 of 28,963 conditions by registered trial count.
34 US clinical trials · 7 currently recruiting · #449 of 28,963 conditions by registered trial count
Neovascular Age-related Macular Degeneration: 34 US clinical trials tracked, 7 recruiting.
Neovascular Age-related Macular Degeneration is the subject of 34 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 13 are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most active sponsor is Hoffmann-La Roche, running 4 of these trials.
Open enrollment snapshot
Neovascular Age-related Macular Degeneration has 34 registered US clinical trials, 7 of them open to new participants right now, about 21% of the total.
- 7
- recruiting participants now
- 21%
- of trials open to enrollment
- 13
- in Phase 3-4 (later-stage)
- 4
- top sponsor: Hoffmann-La Roche
Corpus placement: #449 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Neovascular Age-related Macular Degeneration on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Neovascular Age-related Macular Degeneration is recruiting below its size-band peers.
7 of 34 indexed trials (20.6%) are open to enrollment, against a 39.7% average across 767 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Neovascular Age-related Macular Degeneration trials is spread across many organizations.
Hoffmann-La Roche accounts for 4 of 34 trials (11.8%). 24 distinct sponsors appear on at least one study for this condition label.
-
Typical Neovascular Age-related Macular Degeneration enrolment sits around 69 participants.
Median target enrolment is 69 among the 34 trials that report a genuine target (sentinel values excluded). 19 of those (55.9%) plan for fewer than 100 participants.
-
Neovascular Age-related Macular Degeneration research is mostly interventional.
30 interventional and 4 observational studies make up this index (88.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
34 total, page 1 of 1
Extension Study for the Port Delivery System With Ranibizumab (Portal)
Hoffmann-La Roche
NCT03683251
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
AbbVie
NCT04704921
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
Jaeb Center for Health Research
NCT05904028
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
AbbVie
NCT07007065
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Genentech
NCT04853251
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Skyline Therapeutics (US)
NCT05986864
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
Sanofi
NCT06660667
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
Hoffmann-La Roche
NCT05476926
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Regeneron Pharmaceuticals
NCT06491914
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
Ocular Therapeutix
NCT06495918
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
Ocular Therapeutix
NCT06223958
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
Outlook Therapeutics
NCT05112861
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
Adverum Biotechnologies
NCT05536973
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
Ashvattha Therapeutics
NCT05387837
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
Adverum Biotechnologies
NCT04645212
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
AiViva BioPharma
NCT05698329
Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
AsclepiX Therapeutics
NCT05859776
A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration
Hoffmann-La Roche
NCT03677934
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
Regeneron Pharmaceuticals
NCT02713204
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Outlook Therapeutics
NCT03834753
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
Outlook Therapeutics
NCT04516278
A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD
Alkahest
NCT04331730
Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration
Retina Macula Institute
NCT00764738
ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration
Ophthotech Corporation
NCT00709527
Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)
Retinal Consultants of Arizona
NCT01863199
Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)
Unity Biotechnology
NCT05275205
Neovascular Age-related Macular Degeneration
Oregon Health and Science University
NCT01712035
Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)
University of Miami
NCT00344227
A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe
Hoffmann-La Roche
NCT05569148
Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration
Olix Pharmaceuticals
NCT05643118
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients
Novartis Pharmaceuticals
NCT04635800
Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration
Ocular Therapeutix
NCT04989699
Safety and Tolerability Study for Age-Related Macular Degeneration
Iconic Therapeutics
NCT01485588
Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study
Clearside Biomedical
NCT05131646
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 8 |
| Phase 3 | 11 |
| Phase 4 | 2 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Neovascular Age-related Macular Degeneration right now
7 recruiting of 34 indexed (21% open).
Phase mix: 13 late (III/IV) vs 17 early (I/II) (balanced across stages).
Top sponsor: Hoffmann-La Roche (4 trials), 9 others listed. 34 shown below, recruiting first. #449 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for Neovascular Age-related Macular Degeneration?
PlainTrial tracks 34 US clinical trials for Neovascular Age-related Macular Degeneration, of which 7 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Neovascular Age-related Macular Degeneration?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.